AXL inhibition, in addition to a marked reduction in the endosome-associated Tlr7, Tlr8, and Tlr9, strongly decreased the levels of Tlr1 expression which has been positively associated with the bacterial translocation in MASH patients and proposed as a therapeutic target (26, 27). This evidence concerns the gene TLR1 and metabolic dysfunction-associated steatohepatitis.